SCHEMBL3093022

SCHEMBL3093022

O=C(Nc1ccc(CC(C(=O)O)C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 3/20 0.55
GPR27 Q9NS67 1/20 0.52
KAT6A Q92794 1/20 0.51
NR1H4 Q96RI1 2/20 0.49
LARS1 Q9P2J5 1/20 0.48
PRMT1 Q99873 1/20 0.48
LMNA P02545 1/20 0.47
CA2 P00918 2/20 0.47
MMP2 P08253 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA9 Q16790 1/20 0.46
HPGD P15428 1/20 0.46
ENPP3 O14638 1/20 0.46
ENPP1 P22413 1/20 0.46
ENPP2 Q13822 1/20 0.46
AKR1C3 P42330 1/20 0.46
ITGB3 P05106 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103341 0.90 MMP9 (0.48) MMP9GPR27KAT6ANR1H4LARS1
SCHEMBL3102701 0.89 AR (0.49) MMP9GPR27KAT6ALARS1LMNA
SCHEMBL3090460 0.89 MMP9 (0.49) MMP9GPR27KAT6ANR1H4LARS1
SCHEMBL3102970 0.89 MMP9 (0.46) MMP9GPR27KAT6ANR1H4LARS1
SCHEMBL3093901 0.89 MMP9 (0.46) MMP9GPR27KAT6ANR1H4LARS1
SCHEMBL3101110 0.89 F10 (0.50) MMP9GPR27KAT6APRMT1MEN1
SCHEMBL3096727 0.88 F10 (0.51) MMP9GPR27
SCHEMBL3092113 0.88 MMP9 (0.46) MMP9GPR27KAT6ANR1H4LARS1
SCHEMBL3100522 0.87 MMP9 (0.45) MMP9GPR27KAT6ANR1H4LARS1
SCHEMBL3090840 0.86 LARS1 (0.58) MMP9KAT6ALARS1LMNAMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MMP9 1227/4885GPR27 141/4885KAT6A 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.